Assessing Risk of Bias in Veterinary Randomized Trials

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• The Cochrane Risk of Bias tool (version 2) is the primary framework for assessing methodological quality in veterinary randomized trials, focusing on five core domains: randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result.
• Judgments for each domain are categorized as low risk, some concerns, or high risk, with the overall risk of bias for a specific result determined by the least favorable domain judgment, meaning a single high-risk domain renders the entire result high risk.
• Veterinary trials require specific adaptations to the tool, particularly regarding blinding feasibility (owner and assessor blinding are crucial, while animal blinding is impossible), outcome measurement objectivity (e.g., objective measures like survival time vs. subjective measures like lameness scores), and allocation concealment logistics in group-housed livestock.
• Common failure modes in veterinary randomized trials include inadequate allocation concealment (e.g., using non-opaque envelopes), unblinded outcome assessment (especially for subjective outcomes), differential withdrawal of animals based on perceived treatment efficacy, and selective reporting of favorable results.
• Reporting guidelines such as CONSORT, REFLECT (for livestock), and ARRIVE 2.0 are critical for transparent reporting of trial methods, providing essential information for bias assessment, though adherence to these guidelines does not automatically equate to low risk of bias.
• The assessment of risk of bias is a structured judgment to inform the interpretation of trial results and the confidence that can be placed in them, rather than a simple calculation or an exercise in assigning blame.

Randomized trials are the strongest primary study design for estimating the effects of veterinary interventions, but their credibility depends on the degree to which systematic error has been controlled. Risk of bias assessment is the structured process of judging whether flaws in trial design, conduct, or reporting have produced results that deviate from the true effect. This article provides a practical framework for veterinary researchers who appraise randomized trials, with emphasis on the Cochrane Risk of Bias tool and its domain-specific application to animal studies. It answers the question of how to distinguish a trial whose results can inform clinical decisions from one whose apparent effects are artefacts of methodologic weakness.

The assessment of methodological quality is an essential step before a study's findings can be used, and the choice of an appropriate tool depends on accurate classification of the study type. For randomized controlled trials, including individually randomized and cluster-randomized designs, the Cochrane Risk of Bias tool is the most widely used instrument. The tool's structure reflects a conceptual distinction between bias arising from flaws in how a trial was designed and conducted, and bias arising from how its results were reported. This article covers the tool's domains, their interpretation in veterinary contexts, and the practical decisions a reviewer must make when applying them across species and clinical settings. Non-randomized studies are excluded from this scope.

At a Glance

The Logic of Bias Assessment

Bias is a systematic deviation of an estimated effect from the true effect, and it operates in a direction that cannot be predicted from the magnitude of the deviation alone. A trial with high risk of bias can overestimate or underestimate a treatment effect, and the direction often depends on the nature of the outcome and the mechanism of the bias. For example, failure to conceal allocation can lead to selective enrollment of less severely affected animals into the treatment group, which typically inflates the apparent benefit of the intervention. Conversely, unblinded assessment of a subjective outcome such as lameness score can bias results toward the investigator's expectation, which may favour either arm depending on prior belief.

The Cochrane approach treats bias as a property of a specific result instead of of the trial as a whole. A single trial can produce several results, each with its own risk profile. A primary outcome measured objectively with complete follow-up may be at low risk, while a secondary subjective outcome assessed without blinding may be at high risk. Reviewers must therefore define the result they are assessing, including the outcome, the time point, and the analysis, before applying the tool.

The Cochrane Risk of Bias Tool

The Cochrane Risk of Bias tool, version 2, organizes assessment into five domains for individually randomized trials. Each domain contains signaling questions that guide the reviewer toward a judgment of low risk, some concerns, or high risk. The overall risk of bias for a result is determined by the domain with the least favourable judgment, so a single high-risk domain renders the entire result high risk.

Randomization Process

This domain covers two distinct mechanisms: random sequence generation and allocation concealment. Random sequence generation ensures that each animal or experimental unit has a known and equal probability of assignment to each arm. Allocation concealment ensures that the person enrolling animals cannot know or predict the upcoming assignment. In veterinary trials, allocation concealment is often compromised when the same person who enrols animals also prepares the randomization schedule. A secure method, such as a central web-based system or sequentially numbered opaque sealed envelopes, prevents this failure. The signaling questions ask whether the allocation sequence was random, whether it was concealed until animals were assigned, and whether baseline differences between groups suggest a problem with the randomization process.

Deviations from Intended Interventions

This domain addresses what happens after randomization. Participants may not receive their assigned intervention, or co-interventions may be applied unequally across arms. In veterinary trials, deviations include owner non-adherence to a medication schedule, protocol-mandated rescue analgesia, and crossover of animals between treatment groups. The domain also considers whether the analysis preserved the effect of assignment, which is the intention-to-treat principle. Blinding of caregivers and outcome assessors is a primary mechanism for preventing deviations, but blinding is not always feasible in veterinary practice. A trial of a surgical technique cannot blind the surgeon to the procedure, though it can blind the outcome assessor and the owner. The reviewer must judge whether the observed deviations were likely to bias the result and whether the analysis addressed them appropriately.

Missing Outcome Data

Loss to follow-up is common in veterinary trials, particularly in long-term studies involving client-owned animals. Owners may move, withdraw consent, or fail to return for scheduled assessments. This domain asks whether data were missing for reasons related to the true value of the outcome, whether the proportion of missing data is large enough to bias the result, and whether the analysis used methods such as multiple imputation or inverse probability weighting to address the missingness. A key distinction is between missingness that is unrelated to outcome, such as a client relocating for employment, and missingness that is related to outcome, such as an animal withdrawn because of an adverse reaction to the treatment.

Measurement of the Outcome

The risk of bias in outcome measurement depends on the objectivity of the outcome and the blinding of the assessor. Objective outcomes such as survival time, body weight, or laboratory values are less susceptible to assessor bias, though the method of measurement must be identical across arms. Subjective outcomes such as pain scores, lameness grades, or owner-reported quality of life require blinding of the assessor to protect against differential misclassification. The domain also asks whether the method of measurement was appropriate for the outcome and whether the assessor could have known the assigned intervention. In veterinary trials, a common failure is the use of an owner-reported outcome without blinding the owner to treatment allocation, which is often unavoidable when the treatment has obvious effects such as palatability or visible formulation differences.

Selection of the Reported Result

This domain addresses selective reporting, where multiple analyzes, outcomes, or time points are measured but only a subset is reported. The risk of bias is low when the trial was registered prospectively and the reported results match the pre-specified analysis plan. Veterinary trials are frequently registered in databases such as the Veterinary Clinical Trials Registry or the American Veterinary Medical Association's trial listing, though registration rates remain lower than in human medicine. The reviewer should compare the reported outcomes with those listed in the registration record and with the methods section of the trial report. Discrepancies, such as a primary outcome changed after the trial began or an analysis not described in the protocol, raise the risk of bias.

Species and Setting Considerations

The application of the Cochrane tool to veterinary trials requires adaptation to species-specific realities. Blinding of the animal is not possible, though this is rarely a source of bias because animals do not have expectations about treatment. Blinding of the owner and the veterinarian is feasible in many drug trials using identical placebos, but it fails when the intervention has a distinctive appearance, odour, or route of administration. In livestock production trials, allocation concealment may be complicated by group housing, where animals within a pen cannot receive different treatments without risk of cross-contamination. Cluster randomization at the pen or herd level is often necessary, and the cluster version of the Cochrane tool should be used in these cases. The reporting of livestock trials is supported by the REFLECT statement, which is indexed in the EQUATOR Network's library of reporting guidelines. For all animal research, the ARRIVE guidelines 2.0 specify the minimum information required for transparent reporting, including details of randomization, blinding, and sample size that are directly relevant to bias assessment.

Practical Implications for the Reviewer

A risk of bias assessment is not an exercise in assigning blame to the trial authors. Its purpose is to inform the interpretation of the results and the confidence that can be placed in them. A trial at high risk of bias may still provide useful information, particularly if the direction of the likely bias is understood and the effect size is large enough to withstand the anticipated distortion. Conversely, a trial at low risk of bias may still be uninformative if it is underpowered or if its population does not match the clinical question. The assessment should be reported transparently, with the signaling questions and judgments presented so that readers can verify the reviewer's reasoning. This transparency is consistent with the broader expectation that systematic reviews and evidence syntheses document their methods fully, as described in methodological guidance on quality assessment tools for primary and secondary medical studies.

Building the Review Protocol

A structured protocol prevents drift during assessment. The protocol should specify the tool version, the domains to be judged, the signaling questions to be used, and the criteria for each judgment category. For veterinary trials, the protocol must also define how species-specific features will be handled, such as whether blinding of animal handlers is feasible and whether outcome adjudication can be masked.

The protocol should be registered or dated before assessment begins. Two reviewers working independently is standard practice. Disagreements are resolved by discussion or by a third reviewer. The protocol should state the threshold for disagreement that triggers adjudication, for example any difference between low risk and some concern, or between some concern and high risk.

A pilot phase is advisable. Apply the tool to one or two trials first, compare judgments, and refine the interpretation notes before assessing the full set. This is particularly useful when the review team includes both clinicians and methodologists, because their interpretations of veterinary procedures may differ.

Documenting Judgments with Supporting Text

Each domain judgment requires a free-text justification. The justification should quote or paraphrase the relevant sections of the trial report, state what the reviewer inferred when the report was silent, and explain how the inference was reached. For example, a judgment of low risk of bias for the randomization process might read: "The report states that a computer-generated random sequence was used and that allocation was concealed in sequentially numbered opaque sealed envelopes. No baseline imbalance in signalment or disease severity was apparent."

When the report is silent, the reviewer must decide whether to contact the authors or to judge on the available information. Contacting authors is reasonable for recent trials, but response rates are often low. The protocol should specify a time limit for author responses, after which the trial is judged on the published report alone.

The justification text should also record the clinical reasoning behind the judgment. For the measurement of the outcome domain, the reviewer should note whether the outcome was measured by an automated device, a laboratory assay, or a subjective clinical scale, and whether the assessor was masked to treatment allocation. Species-specific considerations belong in this text. For example, pain scoring in cats often relies on facial expression scales that require video recording, and the feasibility of masking the scorer depends on whether the video captures the catheter site or other treatment indicators.

Handling Cluster and Crossover Designs

Cluster randomized trials require additional considerations within the standard domains. The randomization process domain must assess whether the unit of randomization, such as herd, kennel, or practice, was concealed from the recruiting staff. Baseline comparability of clusters is more fragile than in individually randomized trials, because the number of clusters is often small. The reviewer should check whether the analysis accounted for clustering, typically through multilevel modeling or generalized estimating equations.

Crossover trials present a different set of concerns. The deviations from intended interventions domain must consider carryover effects and period effects. The reviewer should check whether a washout period was included and whether its duration was justified by the pharmacokinetics of the study drug. The missing outcome data domain must consider whether data were missing in a pattern related to period or sequence. The measurement of the outcome domain should assess whether the assessor could have been unblinded by knowing which period the animal was in.

The Role of Reporting Guidelines in Bias Assessment

Reporting guidelines do not assess bias directly, but they support the assessment by defining what information should be present. The CONSORT statement and its extensions, including the REFLECT statement for livestock trials, specify the items that trials should report. When a trial follows these guidelines, the reviewer can judge domains with greater confidence. When a trial does not, the absence of information becomes a signal, although the reviewer must be careful not to equate poor reporting with poor conduct. The EQUATOR Network maintains a comprehensive library of reporting guidelines, and the ARRIVE guidelines provide the equivalent standard for animal research publications.

A trial that reports adherence to CONSORT or ARRIVE still requires domain-by-domain assessment. Reporting guidelines describe what should be reported, not how the trial was actually conducted. A trial can report a flawed method transparently, and the reviewer must judge the method itself.

Common Failure Modes in Veterinary Trials

Several failure modes recur in veterinary randomized trials. The first is inadequate allocation concealment in trials that use sealed envelopes. Envelopes can be opened before the animal is enrolled, particularly in busy practice settings. The reviewer should look for statements about envelope opacity, numbering, and whether the envelopes were opened by someone independent of the enrollment process.

The second is unblinding through laboratory results. In trials where the treatment has a measurable physiological effect, such as changes in serum chemistry or hematology, the laboratory report can reveal the allocation. The reviewer should check whether the laboratory staff were masked and whether the results were reviewed by a masked clinician before outcome assessment.

The third is differential withdrawal. Veterinary trials often have high dropout rates because owners may withdraw animals that are not improving or may request rescue medication. The reviewer should examine whether withdrawal rates differed between groups and whether the reasons for withdrawal were recorded. A trial that excludes withdrawn animals from the analysis without a clear justification should be judged at high risk of bias for missing outcome data.

The fourth is the use of per-protocol analysis when intention-to-treat analysis was planned. The reviewer should check whether the primary analysis followed the intention-to-treat principle and whether the per-protocol analysis was presented as a sensitivity analysis.

Interpreting the Overall Risk of Bias

The overall risk of bias is not a simple sum of domain judgments. The Cochrane approach considers the domains that are most likely to affect the primary outcome. For a trial with a subjective primary outcome, such as owner-assessed lameness or quality of life, the measurement of the outcome domain carries more weight. For a trial with an objective primary outcome, such as survival time or bacterial culture results, the randomization and missing data domains may be more influential.

The reviewer should state the overall judgment explicitly and link it to the domains that drove the decision. A trial judged at high risk of bias in one domain is not automatically unusable, but the review should explain how that domain affects confidence in the specific outcome being considered. The judgment should be reported alongside the effect estimate, so that readers can weigh the evidence accordingly.

Presenting Results in the Review

The results of the bias assessment should be presented in a table that lists each trial, each domain, and the judgment with a brief justification. A traffic-light figure, with green for low risk, yellow for some concerns, and red for high risk, is a common and effective visual format. The table should also record whether the judgment was based on the published report alone or supplemented by author contact.

The review text should describe the pattern of judgments across trials. If most trials are at high risk of bias in the same domain, that pattern should be stated explicitly, because it affects the strength of the conclusions. The review should also state how the bias assessment influenced the synthesis, for example whether trials at high risk of bias were excluded from the primary analysis or included in a sensitivity analysis.

The bias assessment is a judgment, not a calculation. Two experienced reviewers may reach different conclusions from the same report, and the justification text is what makes the assessment reproducible. The goal is not to produce a single score but to provide a transparent, reasoned account of the confidence that can be placed in each trial's results.

Recognized Complications and Failure Modes

Risk of bias assessment fails in predictable ways. The most common is domain misclassification, where a reviewer labels a methodological flaw under the wrong domain. For example, failure to conceal allocation is a randomization process problem, not a deviation from intended interventions problem. The discriminating check is to ask which stage of the trial the flaw affected. Allocation concealment operates before assignment, while blinding of participants operates after assignment.

A second failure mode is the halo effect, where a strong trial in one domain leads the reviewer to downgrade flaws in another. This is detected by scoring each domain independently before forming an overall judgment. A third is criterion drift, where the reviewer applies stricter thresholds to later trials in the same review. Pre-specifying domain criteria in the review protocol and revisiting it during assessment reduces this risk.

A fourth complication is the conflation of reporting quality with conduct quality. A poorly reported trial may have been conducted well, and a well-reported trial may conceal poor conduct. The Cochrane tool assesses risk of bias in the reported study, not the underlying conduct. Reviewers should record when a judgment is based on incomplete reporting and should consider contacting authors for clarification.

Common Errors and Corrective Actions

Less experienced reviewers often judge blinding as low risk whenever the paper states "double-blind," without verifying who was actually blinded. The corrective action is to check each blinding category separately: participants, caregivers, outcome assessors, and analysts. Veterinary trials frequently blind outcome assessors but cannot blind caregivers, particularly in surgical or dietary studies. Each category receives its own judgment.

A second common error is treating all missing outcome data as high risk. Missing data that are balanced between groups and unrelated to the outcome carry lower risk than missing data driven by the outcome itself. The reviewer should examine the proportion missing, the reasons given, and whether the analysis used methods such as multiple imputation or mixed models that accommodate missingness.

A third error is confusing the risk of bias tool with a quality score. The Cochrane approach does not produce a single numerical score, and summing domain judgments is discouraged because it obscures the pattern of strengths and weaknesses. The corrective action is to present each domain judgment separately, as recommended in methodological guidance on assessment tools for primary studies.

A fourth error is failing to distinguish between bias and imprecision. A small trial with wide confidence intervals has imprecision, not bias. The risk of bias assessment addresses systematic error, while precision is addressed during the certainty of evidence evaluation.

Limitations of the Evidence Base

The Cochrane tool was developed for human trials, and its application to veterinary medicine requires adaptation. Blinding of animal participants is impossible, but blinding of owners and outcome assessors is often feasible. The relevance of the "blinding of participants" domain therefore shifts to blinding of owners and caregivers, and this distinction should be documented.

Expert opinion still differs on how to handle trials where the intervention cannot be blinded, such as surgical versus medical comparisons. Some reviewers judge these as high risk across all blinding domains, while others restrict the high risk judgment to outcome domains where assessor blinding was absent. The latter approach is more informative because it separates the unavoidable from the avoidable.

The evidence base for veterinary-specific bias assessment is limited. Most methodological research on bias tools derives from human medicine, and extrapolation to veterinary trials assumes that the same bias mechanisms operate. This assumption is reasonable for measurement-related domains but weaker for domains involving participant behavior, where owner expectations and compliance patterns differ from human self-report. Reporting standards such as the ARRIVE guidelines and the EQUATOR Network library provide a framework for what should be reported, but they do not resolve how to judge bias when reporting is incomplete.

Escalation and Referral

Most risk of bias assessments can be completed by a single reviewer with methodological training. Escalation is warranted when the trial design is complex, such as cluster randomization or crossover designs, where standard domain guidance requires modification. In these cases, consultation with a statistician or an experienced systematic reviewer is appropriate.

Laboratory involvement is indicated when the review depends on interpreting assay methods, such as the validity of a diagnostic test used as an outcome measure. The reviewer should verify whether the assay was validated for the species and sample type studied, and whether the laboratory was blinded to treatment allocation. Species-specific reference resources can clarify whether a given assay is standard for the target species.

Regulatory reporting is rarely triggered by a risk of bias assessment itself. However, if the assessment reveals evidence of data fabrication or serious ethical violations, the reviewer should consult institutional policies and may need to report to the relevant research integrity body. Professional practice resources from organizations such as the AVMA can guide the reviewer on responsible conduct expectations. International standards for animal welfare in research, such as those published by the World Organization for Animal Health, may also be relevant when the trial involved animals in a regulated setting.

Frequently Asked Questions

How much time should I budget for a formal risk of bias assessment in a veterinary systematic review?

A single reviewer familiar with the Cochrane tool typically needs 45 to 90 minutes per trial for the first pass, depending on study complexity and reporting quality. Cluster randomized and crossover designs require additional time because allocation concealment and unit-of-analysis errors must be evaluated separately. Budget at least twice that for the first few trials while calibration is ongoing. Duplicate independent assessment, which is strongly recommended, doubles the time but improves reliability. The methodological quality assessment tools review notes that accurate study type identification is the first priority, so confirm the design before applying the tool. For a review of 20 to 30 trials, plan for two to three working weeks of assessment time including resolution meetings.

What should I do when the original trial protocol or statistical analysis plan is unavailable?

Treat the missing protocol as a reporting limitation, not an automatic high risk judgment. For selection of the reported result, the absence of a protocol makes it impossible to verify pre-specified outcomes, so the domain is often judged as having some concerns or high risk unless the trial was registered prospectively. Check registries such as clinicaltrials.gov or national registers for veterinary trials. If registration exists, compare the registered outcomes with the published report. When neither protocol nor registration exists, document this explicitly in the supporting text and consider contacting the corresponding author. The ARRIVE guidelines specify that protocols and analysis plans should be reported, so their absence is itself informative about reporting culture.

How do I adapt the risk of bias judgment when blinding of personnel is impossible, such as in surgical trials?

Blinding of the surgeon is usually impossible, but this does not automatically make the deviations from intended interventions domain high risk. The key question is whether knowledge of group assignment influenced care beyond the intervention itself. In veterinary surgical trials, assess whether postoperative care, analgesia protocols, and discharge criteria were standardized. Blinding of outcome assessors is often feasible even when the surgeon is unblinded, particularly for radiographic, histopathologic, or laboratory outcomes. For owner-reported outcomes, blinding of owners is essential and usually achievable. The Cochrane approach to methodological quality distinguishes between performance bias and detection bias, and these should be judged separately. Document the specific measures used to standardize co-interventions in the supporting text.

Which domains matter most for field trials in production animals where animals are group-housed?

Group housing creates special problems for the randomization process and deviations from intended interventions domains. If animals are randomised by individual but housed together, contamination of interventions is possible, particularly for behavioral or feed-based interventions. Cluster randomization by pen or herd is often more appropriate, and the analysis must account for clustering. Missing outcome data is a frequent concern in production settings because animals may be culled, sold, or lost to follow-up for reasons related to the outcome. The WOAH terrestrial animal health standards emphasize the importance of clear definitions for health outcomes and follow-up in animal populations. Assess whether the reasons for missing data are balanced between groups and whether the proportion missing exceeds the event rate in the control group.

How should I document risk of bias judgments for an audit trail or regulatory submission?

Record the judgment for each domain, the supporting rationale, and direct quotations from the trial report that inform the judgment. Include the date of assessment, reviewer identity, and version of the tool used. Note any disagreements between reviewers and how they were resolved. Store this documentation separately from the data extraction forms so that bias judgments can be revisited if new information emerges, such as a protocol retrieved from an author. The EQUATOR Network reporting guidelines library provides templates for transparent reporting that can also guide documentation practice. For regulatory submissions, ensure that the assessment covers all prespecified outcomes and that the overall judgment is justified with reference to the domains that drove the decision.

How do I explain a high risk of bias finding to a referring veterinarian or practice owner who wants to use a study's conclusions?

Frame the explanation around confidence instead of fault. State that the study's conclusions may be correct, but the design leaves room for alternative explanations. Give one concrete example, such as lack of blinding leading to differential assessment of outcomes between treatment groups. Explain that a high risk of bias finding does not mean the treatment is ineffective, only that the evidence is not strong enough to guide clinical decisions. Mention that professional veterinary references and specialty college guidelines integrate evidence from multiple studies, so a single flawed trial rarely changes overall recommendations. Offer to identify better designed studies or systematic reviews on the same topic. Avoid technical jargon and focus on the practical question of whether the treatment effect is likely to be real.

Related Clinical & Scientific Guides

• Conducting Systematic Reviews of Veterinary Diagnostic Test Accuracy
• Bias in Veterinary Research: Types, Sources, and Mitigation
• Cluster Randomized Trials in Veterinary Research: Design and Analysis

References and Further Reading

• Comparison of effects of long-term low-fat vs high-fat diets on blood lipid levels in overweight or obese patients: a systematic review and meta-analysis.. 2013.
• Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?. 2020.
• Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators.. 1997.
• A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults.. 2012.
• Effect of the NU-AGE Diet on Cognitive Functioning in Older Adults: A Randomized Controlled Trial.. 2018.
• Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.. 2019.
• ARRIVE Guidelines 2.0 for Reporting Animal Research. PLOS Biology, 2020.
• EQUATOR Network Reporting Guidelines. EQUATOR Network.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Critical Appraisal of Randomized Controlled Trials in Veterinary Medicine
• Cluster Randomized Trials in Veterinary Research: Design and Analysis
• Bias in Veterinary Research: Types, Sources, and Mitigation
• Designing and Analyzing Factorial Trials in Veterinary Research
• Designing Crossover Trials for Veterinary Therapeutics

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.